Kyntra Bio is dedicated to creating innovative, first-in-class medicines for the treatment of chronic, life-threatening, and debilitating conditions, such as mCRPC and anemia associated with LR-MDS.
Our investigational products are not limited to single indications—they represent broader therapeutic platforms designed to target key biological pathways and mediators involved in multiple diseases. This approach enables us to pursue high-impact opportunities across a range of conditions with shared molecular drivers.
